A5046695589- Systemic Sclerosis and Related Diseases
- Systemic Lupus Erythematosus Research
- Immunodeficiency and Autoimmune Disorders
- Monoclonal and Polyclonal Antibodies Research
- Autoimmune and Inflammatory Disorders Research
- Rheumatoid Arthritis Research and Therapies
- Psoriasis: Treatment and Pathogenesis
- Chronic Lymphocytic Leukemia Research
- Salivary Gland Disorders and Functions
- Biosimilars and Bioanalytical Methods
- T-cell and B-cell Immunology
- Autoimmune Bullous Skin Diseases
- Cell Adhesion Molecules Research
- Inflammatory Myopathies and Dermatomyositis
- Spondyloarthritis Studies and Treatments
- Fibromyalgia and Chronic Fatigue Syndrome Research
Lakeridge Health
2013-2024
Elevated levels of type I interferons (IFNs) are a characteristic feature the systemic autoimmune rheumatic diseases (SARDs) and thought to play an important pathogenic role. However, it is unknown whether these elevations seen in anti-nuclear antibody-positive (ANA+) individuals who lack sufficient criteria for SARD diagnosis. We examined IFN-induced gene expression asymptomatic ANA+ patients with undifferentiated connective tissue disease (UCTD) address this question.Healthy ANA- control...
Diagnosis of systemic autoimmune rheumatic diseases (SARD) relies on the presence hallmark anti-nuclear antibodies (ANA), many which can be detected years before clinical manifestations. However, ANAs are also seen in healthy individuals, most whom will not develop SARD. Here, we examined a unique cohort asymptomatic ANA+ individuals to determine whether they share any cellular immunologic features Healthy ANA− controls and (ANA ≥1:160 by immunofluorescence) participants with no SARD...
Upadacitinib (UPA), a selective, reversible, oral Janus kinase (JAK)-1 inhibitor, was approved in 2019 Canada for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). This phase 4 prospective study aimed characterise effectiveness UPA real-world population patients RA. Adults RA who initiated once daily (15 mg) and enrolled Canadian Real-Life post-marketing Observational Study assessing Effectiveness UPadacitinib treating (CLOSE-UP) completed 6-month...
Abstract Background Fatigue is a common symptom of systemic autoimmune rheumatic disease (SARD). Patients with SARD have protracted pre-clinical phase during which progressive immunologic derangements occur culminating in disease. In this study, we sought to determine when fatigue develops and whether its presence correlates inflammatory factors or predicts progression. Methods Anti-nuclear antibody (ANA)-negative healthy controls (HCs) ANA-positive participants no criteria, at least one...
The Canadian Tofacitinib for Rheumatoid Arthritis Observational (CANTORAL) is the first prospective, observational study assessing tofacitinib. objective was to assess effectiveness and safety moderate severe rheumatoid arthritis (RA). Coprimary secondary outcomes are reported from an interim analysis.
<h3>Background</h3> Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trials and usually varies over time. <h3>Objectives</h3> To describe the profile of psoriatic arthritis (PsA) patients selected for treatment with infliximab (IFX), golimumab (GLM) or ustekinumab (UST) Canadian routine care long-term real-world effectiveness safety these agents. <h3>Methods</h3> 462 PsA treated IFX, GLM UST were enrolled into Biologic Treatment...
<h3>Background</h3> The systemic autoimmune rheumatic diseases (SARD; Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren9s Disease, Sclerosis) are proposed to have a prolonged period of pre-clinical autoimmunity culminating in clinical disease. Evidence from disease-specific studies (e.g., SLE, RA) suggests that the phase is marked by accrual immunological abnormalities such as pathogenic auto-antibodies (auto-Ab). Little known about cellular derangements accompany transition benign...
<h3>Background</h3> Patients with systemic autoimmune rheumatic diseases (SARD) often have a prolonged pre-clinical phase during which they are anti-nuclear antibody (ANA)<sup>+</sup> but lack clinical symptoms. It has been proposed that progression from asymptomatic autoimmunity to disease is accompanied by immunologic changes could be used as predictors of development. Elevated levels interferon (IFN)-induced gene expression, termed the IFN signature, found in several SARD conditions, and...
<h3>Background</h3> Patients with systemic autoimmune rheumatic diseases (SARD) often have a prolonged pre-clinical phase during which they are anti-nuclear antibody (ANA)<sup>+</sup> but lack clinical symptoms. Here we sought to determine whether ANA<sup>+</sup> individuals who sufficient symptoms for SARD diagnosis share the B cell phenotypic changes seen in SARD. <h3>Materials and methods</h3> Healthy controls (HC) who: 1) lacked of (ANS); 2) had at least one symptom (UCTD); or 3)...
<h3>Background</h3> Patients with systemic autoimmune rheumatic diseases (SARD) often have a prolonged pre-clinical phase during which they are anti-nuclear antibody (ANA)<sup>+</sup> but lack clinical symptoms. It has been proposed that progression from asymptomatic autoimmunity to disease is accompanied by immunologic changes could be used as predictors of development. Previous studies indicate number B cell phenotypic seen in SARD patients including the proportions various naïve and...
<h3>Background</h3> Systemic lupus erythematosus (SLE) is characterised by chronic B cell stimulation and hyperactivity. Due to the complexity variability observed during course of SLE, reliable accurate biomarkers for diagnosis disease management are required. Previously, increased concentrations polyclonal serum free light chains (FLC), a marker immune status renal function, have been reported be elevated in SLE patients<sup>1</sup>. <h3>Objectives</h3> To compare FLC levels patients with...
<h3>Background</h3> The diagnosis of Systemic Autoimmune Rheumatic Diseases (SARD), including Lupus Erythematosus (SLE), relies on the presence ANAs, many which can be detected years before clinical manifestations. However, ANAs are also seen in healthy individuals most whom will not develop SARD. A number cellular immune changes SARD, and thus could constitute potential biomarkers/treatment targets for however it is known at what point disease progression these develop. <h3>Methods</h3>...
<h3>Background</h3> Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trials and usually varies over time. <h3>Objectives</h3> To describe the profile of rheumatoid arthritis (RA) patients treated with infliximab (IFX), golimumab subcutaneous (GLM) or intravenous (GLM-IV) Canadian routine care, along its effectiveness safety. <h3>Methods</h3> 1577 RA IFX, GLM GLM-IV were enrolled into Biologic Treatment Registry Across Canada...